We invite you to meet with the Cellectricon team in exhibit stand 1331 or to stop by our recommended posters:
Visit event site
Cellectricon, a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and CNS disease, has appointed Professor Henrik Zetterberg to its scientific advisory board. Professor Zetterberg brings extensive expertise in Alzheimer’s disease and other neurodegenerative brain disorders. (more…)
Thursday May 3 @ 3 pm CEST (9 am EDT)
Join our webinar to:
- Learn about pain in rheumatoid arthritis and mouse models of arthritis-associated pain.
- Gain knowledge on how autoantibodies can increase neuronal excitability through multiple mechanisms.
- Gain insight into how “reverse translational” approaches can generate new insights to disease and pain pathology.
Camilla Svensson, Associate Professor and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology, Karolinska Institutet.
Registration for this event is now closed. Contact us to learn more.
To further enhance Cellectricon’s expertise in Chronic Pain drug discovery, the company is today announcing the addition of another highly respected specialist, Professor Camilla Svensson, to its scientific advisory board.
Cellectricon has signed a license agreement with Fluicell AB, granting the exclusive right, inter alia, to sell the Dynaflow Resolve technology worldwide and to use the related IP rights.
The Dynaflow Resolve system is considered by many, to be the premier secondary ion channel screening platform on the market, offering high time resolution for any cell type, any ion channel, and in any patch clamp configuration. Launched in 2004, the Dynaflow platform is an established product with a global user base within big pharma and biotech companies. The Dynaflow platform is complementary to Fluicell´s BioPen system for single-cell-based discovery using optical readouts such as fluorescence microscopy. Both are state-of-the art microfluidic-based technologies which appeal to discerning medical, biology and pharma professionals worldwide, that wish to get the most out of their experiments.
Date: Nov 11, 2017
Presentation Time: 1:00 pm – 2:00 pm
Presentation Number: 039.09
Poster Board Number: D58
Modulators of synaptic transmission, acting at various molecular targets, have great potential for development as novel therapeutic agents in an extensive range of CNS diseases, and the search for novel specific pharmacological agents is of widespread interest. However, traditional high throughput screening approaches primarily rely on heterologous expression systems which lack the ability to replicate synaptic complexity. Thus there is a need to develop screening systems that can evaluate compounds on measures of synaptic transmission.
Date: Nov 14, 2017
Presentation Time: 9:00 am – 10:00 am
Presentation Number: 486.14
Poster Board Number: AA9
Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting. We therefore developed a humanized screening assay with sensory neurons derived from human induced pluripotent stem cells (hiPSCs). The resulting assay can be applied in screening to identify compounds that change a disease phenotype, such as neuronal excitability, rather than the activity of specific targets.
Date: Nov 15, 2017
Presentation Time: 4:00 pm – 5:00 pm
Presentation Number: 767.28
Poster Board Number: AA12
Progress in developing higher throughput assays for peripheral pain has largely been limited by the lack of disease-relevant human neuronal cultures. However, with the advent of the human induced pluripotent stem cell (hiPSC) technology, human sensory-like neurons can now be produced in sufficient volumes to enable plate based screening.